Exagen opens Austin office

Exagen Diagnostics (Albuquerque, New Mexico), which develops and commercializes genomic marker-based in vitro diagnostic (IVD) kits for prognosis and prediction of treatment response, has opened a new business office in Austin, Texas.

Exagen's first tests predict the risk of breast cancer recurrence using a prognostic index so that women at both low and elevated risk of recurrence can be identified with high accuracy. The company, which plans to submit its test kits to the FDA for clearance later this year, will be the first to market a set of genomic markers for breast cancer prognosis.

In preparation for its upcoming product launch, Exagen is expanding its sales and customer care departments with the addition of a new vice president of sales, director of customer care, and both technical services and customer services professionals to support the company's test kits.